

sealed with aluminum flip-off type caps. FVIIa may be produced as disclosed in EP patent No. 200,421.

### CLAIMS

- 5 1. A pharmaceutical composition for parenteral administration, which comprises a peptide and dimethyl sulfone.
2. A pharmaceutical composition according to claim 1, wherein the amount of dimethyl sulfone is of from 40 to 400 mM.
- 10 3. A pharmaceutical composition according to claim 2, wherein amount of dimethyl sulfone is of from 125 to 350 mM.
4. A pharmaceutical composition according to claim 1, wherein the composition is a solution.
- 15 5. A pharmaceutical composition according to claim 1, wherein the composition is a suspension.
6. A pharmaceutical composition according to claim 1, which is suitable for administration by injection or infusion.
- 20 7. A pharmaceutical composition according to claim 6, which is suitable for subcutaneous administration.
8. A pharmaceutical composition according to claim 6, which is suitable for intramuscular administration.
- 25 9. A pharmaceutical composition according to claim 6, which is suitable for intravenous administration.
- 30 10. A pharmaceutical composition according to claim 1, which is suitable for pulmonal administration.
11. A pharmaceutical composition according to claim 1, which is suitable for ophthalmic administration or topical administration.
- 35

12. A pharmaceutical composition according to claim 1, wherein the peptide is human growth hormone, GLP-1, GLP-2, insulin, Factor VIIa, Factor VIII, erythropoietin (EPO), glucagon, interleukin, such as interleukin-2 (IL-2), interferon- $\alpha$  or interferon- $\beta$ , or an analogue thereof,  
5 or a derivative of any such peptide or analogue.
13. A pharmaceutical composition according to claim 12, wherein the peptide is human insulin or an analogue thereof, or a derivative of human insulin or the human insulin analogue.
- 10 14. A pharmaceutical composition according to claim 13, wherein the peptide is human insulin.
- 15 15. A pharmaceutical composition according to claim 13, wherein the peptide is Asp(B28)-human insulin.
- 16 16. A pharmaceutical composition according to claim 13, wherein the peptide is Lys(B28) Pro(B29)-human insulin.
- 20 17. A pharmaceutical composition according to claim 13, wherein the peptide is Lys(B3) Glu(B29)-human insulin.
18. A pharmaceutical composition according to claim 13, wherein the peptide is N <sup>$\epsilon$ B29</sup>-tetradecanoyl des (B30)-human insulin.
- 25 19. A pharmaceutical composition according to claim 13, wherein the peptide is Gly(A21) Arg(B31) Arg(B32)-human insulin.
20. A pharmaceutical composition according to claim 13, wherein the peptide is N <sup>$\epsilon$ B29</sup>-litolcholoyl- $\gamma$ -glutamyl des (B30)-human insulin.
- 30 21. A pharmaceutical composition according to claim 12, wherein the peptide is Gly(8)-human GLP-1.
22. A pharmaceutical composition according to claim 12, wherein the peptide is Arg(34), N- $\epsilon$ -  
35 ( $\gamma$ -Glu(N- $\alpha$ -hexadecanoyl))-Lys(26)-human GLP-1(7-37)OH.

23. A pharmaceutical composition according to claim 12, wherein the peptide is Gly(2)-human GLP-2.